Cargando…
Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma Cells
INTRODUCTION: Glioblastoma (GBM) is the most commonly diagnosed primary brain tumor in adults. The 14.6 months median survival period of GBM patients is still palliative due to resistance to the first-line chemotherapeutic agent temozolomide (TMZ). METHODS: The cell growth inhibition effect was asse...
Autores principales: | Zhang, Tongxia, Chai, Jie, Chi, Lingyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883937/ https://www.ncbi.nlm.nih.gov/pubmed/31819508 http://dx.doi.org/10.2147/OTT.S221025 |
Ejemplares similares
-
Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012) -
BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53
por: Nie, Er, et al.
Publicado: (2016) -
The Expression Levels of XLF and Mutant P53 Are Inversely Correlated in Head and Neck Cancer Cells
por: Feng, Sizhe, et al.
Publicado: (2016) -
Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016) -
XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
por: Yang, Sitian, et al.
Publicado: (2017)